News
MPLX: Record Distributable Cash Flow, A 10% Payout Jump, Strong Momentum
It has been a lousy year for income investors relative to the growth theme. The high-dividend factor is down about…
AXA: We See A Promising 2024 (OTCMKTS:AXAHF)
Year-to-date, the STOXX Europe 600 Insurance is up by 8.5% and has delivered a total return, including dividend payment, of…
EMLP: An Example Of How Past Performance Fools More Investors Than A Ponzi Scheme
First Trust North American Energy Infrastructure Fund (NYSEARCA:EMLP) provides investors with an excellent example of why solid ETF research is…
Fedi Mind Tricks: The Fed’s Strategic Bluff Or Massive Blunder?
It didn't take long for the Fed to release a slew of speakers to start the damage control from the…
VDC: Consumer Staples Dashboard For December
This monthly article series shows a dashboard with aggregate industry metrics in consumer staples. It may also serve as a…
Mercury Systems: Upside In Chip War (NASDAQ:MRCY)
In May 2024, I covered Mercury Systems (NASDAQ:MRCY) marking the stock a buy. However, since then the stock has lost…
Aadi Bioscience: New Data Drives A Beaten Company Down, Not Really Justified
Topline Summary Aadi Bioscience (NASDAQ:AADI) is a microcap developmental biotech placing its bets on a single agent, a nanoliposomal encapsulation…
Week In Review: SystImmune Out-Licenses Global Rights For ADC To BMS In $8.4B Deal
Deals and Financings SystImmune, the Seattle arm of Chengdu’s Biokin Pharma, out-licensed global rights (ex-China) for a bispecific ADC to…